East China Pharmaceutical: MC2-01 Cream receives approval for drug clinical trial notification.

East China Pharmaceutical Announcement, the wholly-owned subsidiary Hangzhou Zhongmei East China Pharmaceutical Co., Ltd. received the approval notice of Phase III clinical trial of MC2-01 cream for the treatment of plaque psoriasis in China issued by the National Medical Products Administration. MC2-1 cream is a fixed-dose compound preparation of calcipotriol and betamethasone used for the topical treatment of adult plaque psoriasis, including scalp psoriasis. This product utilizes the unique drug delivery system PAD technology of MC2, making it a convenient water-based cream. The product was approved by the FDA in the United States in 2020, in Europe in 2021, and was approved for listing in Australia in November 2024. This approval is an important milestone in the product development process and will further enhance the company's core competitiveness in the field of autoimmune diseases and topical skin preparations.